| scholarly article | Q13442814 |
| P50 | author | Apostolia Maria Tsimberidou | Q56761627 |
| Michael J. Keating | Q66429598 | ||
| P2860 | cites work | ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia | Q46112511 |
| Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia | Q46378902 | ||
| Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia | Q46421462 | ||
| Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia | Q46817225 | ||
| Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy | Q46847874 | ||
| Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center | Q46958940 | ||
| The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy | Q46965117 | ||
| Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. | Q53572738 | ||
| Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy | Q53962600 | ||
| ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. | Q55036524 | ||
| Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-) | Q58865938 | ||
| Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation | Q68207061 | ||
| Detection of human leukaemia associated antigens in leukaemic serum and normal embryos | Q68632066 | ||
| Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network | Q73330865 | ||
| Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia | Q73720613 | ||
| Fludarabine-Mediated Repair Inhibition of Cisplatin-Induced DNA Lesions in Human Chronic Myelogenous Leukemia-Blast Crisis K562 Cells: Induction of Synergistic Cytotoxicity Independent of Reversal of Apoptosis Resistance | Q73833646 | ||
| Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study | Q78445240 | ||
| Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies | Q78773743 | ||
| Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia | Q80726123 | ||
| The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL) | Q81385815 | ||
| Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis | Q81649289 | ||
| Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions | Q27824806 | ||
| Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia | Q28140129 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study | Q28257337 | ||
| Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia | Q32073465 | ||
| An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma | Q33341057 | ||
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | Q33342242 | ||
| Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine | Q33344258 | ||
| Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. | Q33366608 | ||
| Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia | Q33368885 | ||
| Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study | Q33373186 | ||
| Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. | Q33374160 | ||
| Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia | Q33374227 | ||
| Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia | Q33382608 | ||
| Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | Q33847401 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia | Q35615823 | ||
| ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia | Q35848258 | ||
| Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. | Q36654926 | ||
| Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia | Q37621400 | ||
| Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia | Q37634897 | ||
| Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma | Q38538191 | ||
| Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. | Q40497868 | ||
| Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). | Q40560044 | ||
| Rituximab therapy of patients with B-cell chronic lymphocytic leukemia | Q40597431 | ||
| Rituximab dose-escalation trial in chronic lymphocytic leukemia | Q40604465 | ||
| Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity | Q40713223 | ||
| Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. | Q43837285 | ||
| Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia | Q44089913 | ||
| Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia | Q44242585 | ||
| Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia | Q44397235 | ||
| Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. | Q44513235 | ||
| High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities | Q44613408 | ||
| A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). | Q45129280 | ||
| Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival | Q45287934 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| P304 | page(s) | 2824-2836 | |
| P577 | publication date | 2009-07-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Treatment of fludarabine-refractory chronic lymphocytic leukemia | |
| P478 | volume | 115 |
| Q36025695 | A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo |
| Q37724203 | AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies |
| Q37832570 | Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies |
| Q37842484 | Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies |
| Q37854714 | Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. |
| Q41763842 | Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q37734199 | Chronic lymphocytic leukemia: putting new treatment options into perspective |
| Q33938820 | Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells |
| Q39616548 | Comprehensive Proteomic Analysis of the Effects of Purine Analogs on Human Raji B-Cell Lymphoma |
| Q43242768 | Current and emerging treatments for chronic lymphocytic leukaemia |
| Q84354840 | Dequalinium induces apoptosis in peripheral blood mononuclear cells isolated from human chronic lymphocytic leukemia |
| Q36006445 | Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells |
| Q36019515 | Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia |
| Q36845282 | Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia |
| Q34008866 | Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. |
| Q35136616 | Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies |
| Q34836437 | MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q34116104 | Ofatumumab. |
| Q37844139 | Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly |
| Q43231586 | R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia |
| Q37141887 | Risk categories and refractory CLL in the era of chemoimmunotherapy |
| Q50979257 | Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia |
| Q35718966 | Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). |
| Q37802100 | Standard of care and novel treatments for chronic lymphocytic leukemia |
| Q27312452 | Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model |
| Q37275725 | Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B |
| Q24617708 | The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia |
| Q38192988 | The development of tumor cell characteristics |
| Q38012165 | The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia |
| Q31033615 | The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature |
| Q37964916 | Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Q37829257 | Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia |
Search more.